Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis

By LabMedica International staff writers
Posted on 31 Jul 2026

Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. More...

This creates a persistent gap between disease onset and formal diagnosis, delaying access to appropriate care and support. To help close this gap, a blood-based test is now being integrated into the United Kingdom diagnostic care pathway to support earlier and more accurate assessment.

C2N Diagnostics’ PrecivityAD2 blood test is being used by researchers in the United Kingdom to help accelerate diagnosis and clinical decision-making in primary care and among patients awaiting dementia specialty visits. The initiative is taking place through a collaboration with the Davos Alzheimer’s Collaborative (DAC). Imperial College London is the only UK center participating in DAC’s Accurate Dx program, which also includes four health systems in the United States, two in the European Union, and one in Japan. The UK study began recruiting patients in May.

At the Imperial site, the study Blood Biomarkers for Early and Accurate Diagnosis of Alzheimer’s Disease in Primary Care (BEAD-PC) embeds testing directly within primary care research sites. General practitioners in North West London are ordering PrecivityAD2 alongside standard cognitive assessments before potential referral to dementia specialists at Imperial College Healthcare National Health Service (NHS) Trust. Individuals whose results suggest early-stage cognitive impairment are directed to the Imperial Memory Unit at Charing Cross Hospital for further specialist evaluation. The design is intended to test the accuracy of the blood-based approach specifically within primary care diagnostic pathways.

PrecivityAD2 detects amyloid plaques in the brain with high diagnostic accuracy and is intended for adults aged 50 years and older who present with signs or symptoms of mild cognitive impairment or dementia. By integrating high‑performance blood biomarker testing into routine general practitioner appointments, the program aims to shorten time to diagnosis earlier in the disease course. Beyond immediate clinical aims, the study is structured to generate evidence that could inform how Alzheimer’s diagnostics are delivered at scale across the NHS and other health systems.

“The recent emergence of blood-based biomarkers having comparable sensitivity and specificity to highly specialized imaging and cerebrospinal fluid tests has been a major breakthrough in the field of Alzheimer’s disease. We are indebted to participating patients, their primary and specialist care physicians, as well as U.S.-based C2N Diagnostics as the technology partners in this study. These blood biomarkers hold the promise of transforming the diagnostic and care pathways across the globe, for the benefit of patients and their families,” said Dr. Lefkos Middleton, Professor of Neurology at Imperial.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.